ANG Lifesciences FY26 Results Show ₹11.08 Crore Net Loss, Auditor Flags Defaults

Consolidated Net Loss: ₹11.08 crore
Consolidated Revenue: ₹92.89 crore

Reader Takeaway: Significant liquidity stress and loan defaults mask a profitable pharma segment.

What just happened

ANG Lifesciences India Limited announced its audited financial results for the fiscal year ended March 31, 2026. The company reported a consolidated net loss of ₹11.08 crore on revenues of ₹92.89 crore. Standalone operations also recorded a net loss of ₹4.72 crore.

Why this matters

The results highlight ongoing financial challenges for the company. Crucially, the statutory auditor issued an 'Emphasis of Matter' report, drawing attention to several critical issues. These include a substantial loan default amount of ₹25.86 crore with HDFC Bank and the non-payment of statutory dues for over six months. The auditor also explicitly mentioned conditions that may affect the company's liquidity position.

The backstory

ANG Lifesciences has faced financial stress over the last two fiscal years. The company operates in two segments: Pharmaceuticals, which is its core revenue driver, and Printing and packaging. While the pharmaceutical segment reported a profit of ₹1.25 crore, the printing and packaging segment incurred a loss of ₹5.84 crore, impacting overall profitability.

What changes now

Investors will be closely watching the company's efforts to address its debt obligations and statutory dues. The auditor's concerns signal potential financial instability and liquidity risks that require immediate attention. The company has also not appointed an internal auditor as mandated by the Companies Act, 2013.

Risks to watch

The primary risks include the company's ability to regularize its defaulted loan payments, settle outstanding statutory dues, and manage the losses from its printing and packaging division. The auditor's explicit mention of liquidity risk is a significant red flag.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

• Consolidated Revenue (FY 2026): ₹92.89 crore
• Consolidated Net Loss (FY 2026): ₹11.08 crore
• Outstanding Loan Default (as on March 31, 2026): ₹25.86 crore

What to track next

Investors should monitor any announcements regarding debt resolution plans, payments towards statutory dues, and performance improvements in the packaging segment. The company's ability to comply with governance norms, such as appointing an internal auditor, will also be critical.